By: Fresenius Kabi
With support from: Havas Life Medicom
By: Celgene UK
By: Teva Pharmaceuticals Europe
With support from: VCCP Health
By: Celgene UK
By: Sirtex
With support from: 90TEN and Denova Strategy
By: Sirtex
With support from: 90TEN and Denova Strategy
Bowel cancer that spreads to the liver is one of the biggest cancer killers in the UK and innovative solutions are needed that can offer extended survival for patients. SIR-Spheres microspheres is a radiotherapy procedure that delivers millions of microscopic radioactive beads directly into tumours in the liver which can significantly extend life. With awareness of the procedure low, there was a clear need to educate patients and healthcare professionals about this life-extending treatment while helping them to understand where and how they can access it.
By developing an integrated product campaign that mobilised clinical advocates, supported patients to tell their story and harnessed the power of the media, Sirtex, makers of SIR-Spheres, saw a dramatic increase in awareness among patients and physicians and referrals for the procedure.
This was a strong campaign for unique products that made powerful use of mass media for a very local-focused programme that achieved results. All in all it was a good example of raising treatment option awareness.
Entry deadline | 26 August 2022 |
Extended entry deadline | 2 September 2022* *additional fee applies |
Judging Day | 6 October 2022 |
Company/Team of the Year Interviews | 21 October 2022 |
PMEA Event | 23 November 2022 |